Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.3652W HIGH $35.83
Volume
2.16 M
Value Traded
14.57 M
Short % Float
25.31%
-40.89%Week
-43.91%1 Month
-50.4%3 Month
-34.37%6 Month
+11.38%5 Year
+11.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
823.93 M
EPS (TTM)
-3.32
P/E Ratio
-
Ent. Value
450.81 M
Total Shares
49.31 M
Float Shares
34.64 M
Insiders
29.76%
Institutions
78.44%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AVBP Catalyst Timeline
Dated clinical, regulatory and corporate events for ArriVent BioPharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ArriVent BioPharma, Inc.
101Total events
7Upcoming
24Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Safety Data UpdateFirmonertinibApprovedClinical Data
FURVENT safety data consistent with prior firmonertinib studies
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▼Primary Endpoint MissedFirmonertinibApprovedClinical Data
FURVENT Phase 3 did not meet primary endpoint of PFS by BICR
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▲Secondary Endpoint DataFirmonertinibApprovedClinical Data
Clinical benefit observed on secondary endpoints in FURVENT
first-line EGFR exon 20 insertion mutant non-squamous NSCLCsource ↗
▲Trial InitiationARR-217Trial
Phase 1b dose optimization initiated for ARR-217
gastrointestinal malignanciessource ↗
▲Partnership / LicenseARR-002Corporate
Greater China license agreement with Allist for ARR-002
▲Trial InitiationARR-002Trial
First patient dosing with ARR-002 expected in Q3 2026
ovarian and endometrial cancerssource ↗
◆Dose Finding UpdateARR-217Trial
Initiate Phase 1 dose optimization for ARR-217
gastrointestinal malignanciessource ↗
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC
first-line EGFR exon 20 insertion mutant NSCLCsource ↗
▲IND ClearanceARR-002IND
FDA IND clearance for ARR-002 in May 2026
ovarian and endometrial cancerssource ↗
◆Poster PresentationPresentation
Poster presentation on Exatecan Payload-Based ADCs with AQUALINK platform at AACR 2026
◆Poster PresentationFirmonertinibApprovedPresentation
Poster presentation on discovery and characterization of firmonertinib at AACR 2026
EGFR exon 20 insertion mutant non-small cell lung cancersource ↗
◆Oral PresentationARR-002Presentation
Oral presentation by Aarvik on ARR-002 at AACR Clinical Research Mini Symposium
ovarian and endometrial cancerssource ↗
◆Poster PresentationARR-002Presentation
Poster presentation of AV-P138-ADC (ARR-002) at AACR 2026
ovarian and endometrial cancerssource ↗
◆Poster PresentationARR-002Presentation
Poster presentation on ARR-002 (AV-P138-ADC) at AACR 2026
ovarian and endometrial cancerssource ↗
●Poster PresentationFirmonertinibApprovedPresentation
Preclinical data for firmonertinib presented at AACR
EGFR mutant NSCLCsource ↗
●Poster PresentationARR-002Presentation
Preclinical data for ARR-002 presented at AACR
ovarian and endometrial cancerssource ↗
●Oral PresentationARR-002Presentation
Oral presentation of ARR-002 data at AACR Clinical Research Mini Symposium
ovarian and endometrial cancerssource ↗
▲First Patient DosedARR-217Trial
First patient dosed with ARR-217 in Phase 1
gastrointestinal malignanciessource ↗
▲FDA ApprovalFirmonertinibApprovedFDA Decision
NMPA accelerated approval in China for second-line EGFR exon 20 insertion mutations
second-line EGFR exon 20 insertion mutations NSCLCsource ↗
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline data expected from Phase 3 FURVENT trial
non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutationssource ↗
▲First Patient DosedFirmonertinibApprovedTrial
First patient dosed in global pivotal Phase 3 ALPACCA trial of firmonertinib for first-line EGFR PACC mutant NSCLC
EGFR PACC mutant non-small cell lung cancersource ↗
▲First Patient DosedFirmonertinibApprovedTrial
First patient enrollment expected in global registrational Phase 3 ALPACCA trial
non-small cell lung cancer (NSCLC) with EGFR PACC mutationssource ↗
▲Oral PresentationFirmonertinibApprovedPresentation
Final analysis of firmonertinib monotherapy data from Phase 1b FURTHER trial presented at WCLC 2025
non-small cell lung cancer (NSCLC) harboring EGFR PACC mutationssource ↗
◆Oral PresentationFirmonertinibApprovedPresentation
Present final PACC Phase 1b data at World Conference on Lung Cancer
EGFR PACC mutant NSCLCsource ↗
▼Equity OfferingCorporate
Proposed $75 million public offering of common stock and pre-funded warrants
▲First Patient DosedFirmonertinibApprovedTrial
Enroll first patient in global pivotal Phase 3 PACC study
EGFR PACC mutant NSCLCsource ↗
◆R&D DayFirmonertinibApprovedPresentation
Virtual investor event on firmonertinib path forward for EGFR PACC mutant NSCLC
EGFR PACC mutant non-small cell lung cancersource ↗
◆Oral PresentationFirmonertinibApprovedPresentation
Virtual webinar presenting interim firmonertinib monotherapy data from FURTHER trial
EGFR PACC mutant non-small cell lung cancersource ↗
▲Topline ReadoutFirmonertinibApprovedClinical Data
Positive interim firmonertinib monotherapy data from FURTHER trial
EGFR PACC mutant non-small cell lung cancersource ↗
▲Enrollment CompleteFirmonertinibApprovedTrial
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations
first-line NSCLC harboring EGFR exon 20 insertion mutationssource ↗
◆Timing GuidanceFirmonertinibApprovedPresentation
Clinical development plan for PACC program to be provided in Q2 2025
first-line EGFR PACC mutant NSCLCsource ↗
▲Enrollment CompleteFirmonertinibApprovedTrial
Target enrollment of 375 patients achieved in global pivotal Phase 3 study FURVENT
first-line NSCLC with EGFR exon 20 insertion mutationssource ↗
▲Partnership / LicenseMRG007Corporate
Exclusive global license outside of Greater China for MRG007
gastrointestinal cancerssource ↗
▲Enrollment CompleteFirmonertinibApprovedTrial
Enrollment completed in FURVENT Phase 3 study
first-line EGFR exon20 insertion mutant non-small cell lung cancersource ↗
◆Topline ReadoutFirmonertinibApprovedClinical Data
Topline data expected in 2025 for global pivotal Phase 3 study
first-line NSCLC harboring EGFR exon 20 insertion mutationssource ↗
◆Oral PresentationFirmonertinibApprovedPresentation
Updated data presentation for firmonertinib in first-line EGFR PACC mutant NSCLC including PFS and duration of response
first-line EGFR PACC mutant NSCLCsource ↗
Past FDA Catalysts and PDUFA Decisions
How AVBP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-04-21 | firmonertinib | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$612M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 21%
Micro Cap(rank 139 of 658)
Percentile Rank
ArriVent BioPharma, Inc. carries a moderate pipeline score (48/100), with $1.5B risk-adjusted pipeline value, led by Firmonertinib in Non-small Cell Lung Carcinoma (Phase 3), across $103B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Firmonertinib Small moleculeNCT04858958 | NSCLC | Phase 3 | ACTIVE NOT_RECRUITING | 468 | Feb 28, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every AVBP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| firmonertinib BreakthroughOrphan | EGFR exon 20 insertion mutant NSCLC | Phase 3 | 2026-10-06 | TEAE Grade ≥ 3: firmonertinib 240mg 52%, firmonertinib 160mg 53%, control arm 55%; TRAE Grade ≥ 3: firmonertinib 240mg 26%, firmonertinib 160mg 22%, control arm 40%Read More | ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLCRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HILLHOUSE INVESTMENT MANAGEMENT, LTD.10% Owner | Sell | -555,555 3,929,117 held | $23.37 | 12/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in AVBP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.9 % (35.7 %) | 105.17 M | 3.03 M |
AVBP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AVBP ranks across every disease it competes in
Competitive Position is a premium feature
See how AVBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAVBP News
AVBP▼ -47%on this news
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib for treating EGFR exon 20 insertion mutant NSCLC did not meet its primary endpoint of progression-free survival. However, secondary endpoints showed some clinical benefit, including a trend towards improved overall survival. The safety profile remained consistent with prior studies, with no new safety signals identified.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2026 Financial Results
ArriVent BioPharma reported its second quarter 2026 financial results, highlighting significant advancements in its clinical pipeline. The company anticipates topline Phase 3 data for firmonertinib in treating EGFR exon 20 insertion mutant NSCLC in the second half of 2026. Additionally, ARR-217 has progressed to Phase 1b dose optimization, while ARR-002 is set to begin dosing its first patient in Q3 2026. The company maintains a solid financial position with $373.1 million in cash.
Read more →AVBPArriVent BioPharma Reports First Quarter 2026 Financial Results
ArriVent BioPharma reported its Q1 2026 financial results, highlighting significant advancements in its clinical pipeline. The company anticipates pivotal Phase 3 data for firmonertinib in mid-2026 and has received IND clearance for ARR-002, a dual-targeting ADC. Financially, ArriVent maintains a robust cash position to support operations through late 2027.
Read more →AVBPArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
ArriVent BioPharma has received FDA clearance for its investigational drug ARR-002, a tetravalent antibody-drug conjugate targeting MUC16 and NaPi2b. This ADC aims to treat ovarian and endometrial cancers, showing promising preclinical results in terms of efficacy and safety. A Phase 1 trial is expected to begin in the second half of 2026.
Read more →AVBPAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026
Aarvik Therapeutics will present at the AACR Annual Meeting 2026, showcasing its ADC capabilities. The company will feature two posters and an oral presentation, focusing on its MUTTA™ and AQUALINK™ platforms. These presentations aim to demonstrate advancements in cancer therapies, particularly for ovarian and endometrial cancers, through innovative dual-target ADCs.
Read more →AVBPArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
ArriVent BioPharma announced two poster presentations at the 2026 AACR Annual Meeting, focusing on firmonertinib, an EGFR inhibitor, and ARR-002, a dual-target ADC. Firmonertinib shows significant potential against EGFR mutations, while ARR-002 exhibits superior efficacy in ovarian cancer models. Both candidates are advancing towards clinical evaluation.
Read more →AVBPArriVent BioPharma Reports Full Year 2025 Financial Results
ArriVent BioPharma reported its financial results for the year ending December 31, 2025, highlighting significant progress in the development of firmonertinib for treating uncommon EGFR mutations in NSCLC. The CEO noted that firmonertinib is advancing towards potential registration, with pivotal trial data expected in mid-2026. The company's portfolio also includes an antibody-drug conjugate targeting gastrointestinal cancers, reflecting its commitment to addressing high unmet medical needs in oncology. The organization is well-positioned with a strong balance sheet and a cash runway expected to last into Q3 2027.
Read more →AVBPArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
ArriVent BioPharma has initiated the global pivotal Phase 3 ALPACCA trial, dosing the first patient with firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). This trial aims to evaluate firmonertinib against current treatment options, addressing a significant unmet need in this patient population. The study's endpoints include overall response rate and progression-free survival.
Read more →AVBPArriVent BioPharma Reports Third Quarter 2025 Financial Results
ArriVent BioPharma reported strong financial results for Q3 2025, highlighting progress in its firmonertinib program for EGFR-mutant non-small cell lung cancer (NSCLC). The company is conducting pivotal Phase 3 trials for both PACC mutant and exon 20 insertion mutant NSCLC. Their lead candidate firmonertinib, recently granted FDA Breakthrough Therapy Designation, aims to fulfill significant unmet needs in these underserved populations. Additionally, the firm is advancing its antibody-drug conjugate (ADC) pipeline, projecting further developments toward clinical trials.
Read more →AVBPArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma has appointed Brent S. Rice as Chief Commercial Officer, bringing over 25 years of experience in the biotechnology sector. Rice's prior role at Autolus Therapeutics involved leading global commercialization strategies. His expertise is expected to strengthen ArriVent's commercial foundation as the company approaches the potential approval of firmonertinib for treating EGFR mutant non-small cell lung cancer.
Read more →AVBPArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
ArriVent BioPharma presented promising final analysis data from the Phase 1b FURTHER trial for firmonertinib, an oral EGFR inhibitor, at the 2025 World Conference on Lung Cancer. The study showed a prolonged progression-free survival of 16 months in patients with EGFR PACC mutations. The company plans to initiate a Phase 3 trial for these patients later this year.
Read more →AVBPArriVent BioPharma Reports Second Quarter 2025 Financial Results
ArriVent BioPharma reported its financial results for Q2 2025, highlighting the progress of firmonertinib, which is advancing towards registration with promising interim data from the Phase 1b trial. The company plans to present final data at the World Conference on Lung Cancer and is set to enroll patients in a pivotal Phase 3 study. Additionally, the ADC pipeline is progressing, with the first patient dosed for ARR-217.
Read more →AVBPArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
ArriVent BioPharma has announced that topline data from its pivotal Phase 3 FURVENT study on firmonertinib for first-line NSCLC with EGFR exon20 insertion mutations is expected in early 2026. The study, which has completed enrollment, aims to evaluate progression-free survival compared to standard chemotherapy. Firmonertinib has also received FDA Breakthrough Therapy Designation for this indication.
Read more →AVBPArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma has announced the pricing of a public offering, raising approximately $75 million through the sale of common stock and pre-funded warrants. The offering is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, with a closing date expected around July 3, 2025. Proceeds will be used to further develop firmonertinib and other pipeline projects.
Read more →AVBPArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants
ArriVent BioPharma, Inc. has announced its intention to conduct a public offering of $75 million in common stock and pre-funded warrants. The proceeds will be utilized to advance its lead therapeutic candidate, firmonertinib, amidst other pipeline initiatives. Major financial firms, including Goldman Sachs and Citigroup, are managing the offering, which is contingent on market conditions. This move reflects the company's strategy to enhance its capabilities in the biopharmaceutical sector.
Read more →AVBP▼ -9.6%on this news
Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal
Arrivent BioPharma has announced positive interim results from its Phase 1b study of firmonertinib for treating EGFR PACC mutant non-small cell lung cancer (NSCLC). The study reported a median progression-free survival of 16 months and notable central nervous system activity, with a significant proportion of patients achieving complete and overall responses. Based on these encouraging findings, Arrivent plans to advance firmonertinib into a global pivotal Phase 3 study, with patient enrollment expected to begin in the second half of 2025. The company aims to address unmet medical needs in this underserved patient population.
Read more →AVBP▼ -9.6%on this newsshared move
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
ArriVent BioPharma announced a virtual investor event to discuss the clinical program for firmonertinib, targeting EGFR PACC mutant non-small cell lung cancer (NSCLC). The event is scheduled for June 23, 2025. Firmonertinib has shown promise in treating various EGFR mutations and has received significant regulatory designations. The company aims to address the unmet needs of patients with uncommon mutations.
Read more →AVBPArriVent BioPharma Reports First Quarter 2025 Financial Results
ArriVent BioPharma reported its financial results for the first quarter of 2025, highlighting its progress in oncology, particularly with firmonertinib. The company has completed enrollment in a global pivotal Phase 3 study and anticipates presenting updated data regarding efficacy metrics later in the year. Despite a significant increase in net loss and operating expenses, the firm is preparing for potential near-term milestones with both firmonertinib and a newly acquired antibody drug conjugate, ARR-217. The financial outlook remains cautious due to inherent risks associated with forward-looking statements.
Read more →AVBPArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
ArriVent BioPharma announced the appointment of Dr. Merdad Parsey to its Board of Directors. Dr. Parsey, with decades of experience in leading clinical development, is expected to play a critical role as the company advances its lead candidate, firmonertinib, and its antibody drug conjugate pipeline. His background includes key positions at prominent biopharmaceutical companies and a strong academic foundation in immunology. The company aims to address significant unmet medical needs in cancer treatment with its differentiated therapeutic candidates.
Read more →AVBP▼ -6.7%on this news
ArriVent BioPharma Reports Full Year 2024 Financial Results First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations Global pivota
ArriVent BioPharma reported its full year 2024 financial results, highlighting substantial advancements in its clinical programs, particularly for firmonertinib, which shows promising efficacy against specific EGFR mutations in NSCLC. The company achieved target enrollment in a pivotal Phase 3 study and is planning to provide updates on future investigation plans. Additionally, ArriVent bolstered its ADC pipeline, demonstrating a commitment to addressing unmet medical needs in cancer therapy. The firm continues to progress toward significant clinical milestones in the upcoming year.
Read more →About ArriVent BioPharma, Inc.
Headquarters18 CAMPUS BLVD., NEWTOWN SQUARE, PA, 19073-3269
BIOPHARMAWATCH ELITE PLUS
Trade the next AVBP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime